Phase 3 trial in 549 patients with HER2-negative recurrent or metastatic breast cancer: oral paclitaxel DHP107 was non-inferior to IV paclitaxel for PFS (median 10.0 vs 8.5 months; HR 0.869). DHP107 had more neutropenia and GI effects, less neuropathy.
RCTn = 549
Xu et al. OPTIMAL: a multinational phase III study of oral paclitaxel (DHP107) versus intravenous weekly paclitaxel in HER2-negative recurrent or metastatic breast cancer